hep c dispute, page-10

As the Biocryst shareholders correctly suggested, given the scale of Hep C payments thus far, they could easily payout Biocryst/Biota Hep C program with lunch money. Give $$ to Biocryst for their program, and $$ to Biota to go away.

Talk is around the town that due to the high profile safety failures on Nucs, maybe people will be less inclined to invest heavily on other Nucs. Maybe all Nucs might have inherent safety issues?

Maybe non-Nucs might become more attractive... making our program more attractive?

The main difference between Nucs and Non-Nucs is Nucs are supposed to be less exposed to resistance issues. But Biota's presso says its Non-Nuc has good non-resistance attributes.

Lots of things can happen in this space. Watch this space.